TNF Pharmaceuticals, Renova Health partner using AI for drug development

TNF Pharmaceuticals (TNFA) announced a collaboration with Renova Health using AI and machine learning technologies to identify high-risk patient groups for studies of isomyosamine, aimed at preserving muscle mass during GLP-1 treatment. The partnership analyzes data from 30,000 patients to optimize recruitment and accelerate isomyosamine drug development. Renova’s platform identifies patient subsets based on underlying conditions, acute events, and medication profiles.